A Model for Estimating the Risk of Gastrointestinal Bleeding for Patients on Oral Anticoagulants and Interacting Medications
Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy · 2026-11 · 46 (11)
DOI: 10.1002/phar.70205 ↗Kurz gefasst
Fachartikel in der Zeitschrift Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy, online erschienen am 25.10.2026. Verfasst von Ainhoa Gomez-Lumbreras und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacotherapy, College of Pharmacy, University of Utah, Salt Lake City, Utah, USA. Hauptthemen laut MEDLINE: Gastrointestinal Hemorrhage, Anticoagulants. Die Arbeit nennt 120 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: AHRQ HHS, Agency for Healthcare Research and Quality.
Abstract (Originalsprache)
Introduction
Pharmacodynamic drug–drug interactions (DDI) in patients receiving oral anticoagulants (OAC) may increase the risk of gastrointestinal bleeding (GIB). The purpose of this study was to develop and validate a GIB model for patients receiving OACs.
Methods
A risk model, D rug I nteractions in O ral A nti C oagulants for Risk of G astro i ntestinal B leeding (DIOAC‐GIB), was developed to predict GIB based on interacting medications and other patient‐specific risk factors for patients on OAC. Inputs for the model were obtained using random‐effect meta‐analysis or from the literature for the following attributes: exposure to nonsteroidal anti‐inflammatory drugs (NSAIDs); selective serotonin reuptake inhibitors/serotonin‐norepinephrine reuptake inhibitors (SSRI/SNRIs); aspirin, antiplatelet medications, and proton pump inhibitors (PPIs); age; and GIB history. The model was correlated to existing OAC models (HAS‐BLED and DOAC score).
Results
GIB risk for OACs was based on pivotal trials (1.16% for apixaban; 3.15% for rivaroxaban; 3.00% for dabigatran; 3.31% for edoxaban; and 2.00% for warfarin). The odds ratio (OR) of GIB for NSAIDs ranged from 1.16 (95% confidence interval [CI]: 0.84–1.61) for celecoxib to 20.67 (95% CI: 14.56–29.34) for ketorolac. ORs for GIB among SSRI/SNRIs ranged from 1.31 (95% CI: 1.07–1.62) for paroxetine to 1.50 (95% CI: 1.32–1.70) for venlafaxine. Risk of GIB also included persons > 65 years of age (relative risk = 2.50, 95% CI: 1.2–5.5); history of GIB (OR = 5.14, 95% CI: 3.92–6.73); exposure to aspirin (OR = 1.31, 95% CI: 0.93–1.85), antiplatelet medications (OR = 1.97, 95% CI: 1.73–2.25), and corticosteroids (OR = 1.69, 95% CI: 1.53–1.87); and PPIs reduced GIB risk (OR = 0.67, 95% CI: 0.62–0.74). Correlations between the DIOAC‐GIB and HAS‐BLED and DOAC scores were 0.5 for both ( p < 0.01).
Conclusion
DIOAC‐GIB is a novel GIB‐risk model that incorporates pharmacodynamic OAC DDIs to assist clinicians and patients to determine a therapeutic plan while accounting for GIB risk. DIOAC‐GIB correlates with other bleeding risk scores and may help identify high‐risk patients who may benefit from tailored prescribing.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pharmacotherapy, College of Pharmacy, University of Utah, Salt Lake City, Utah, USA.
- Department of Biomedical Informatics, Vanderbilt University Medical Center, Nashville, Tennessee, USA.
- Department of Biomedical Informatics, School of Medicine, University of Utah, Salt Lake City, Utah, USA.
ORCID-Profile: Ainhoa Gomez-Lumbreras, Abdelrahman G Tawfik, Thomas Reese, Daniel M Witt, Guilherme Del Fiol, Daniel C Malone
Förderung
- AHRQ HHS
- Agency for Healthcare Research and Quality
Zitieren
APA
Gomez-Lumbreras, A., Tawfik, A. G., Reese, T., Witt, D. M., Del Fiol, G., & Malone, D. C. (2026). A Model for Estimating the Risk of Gastrointestinal Bleeding for Patients on Oral Anticoagulants and Interacting Medications. Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy, 46(11). https://doi.org/10.1002/phar.70205
Vancouver
Gomez-Lumbreras A, Tawfik AG, Reese T, Witt DM, Del Fiol G, Malone DC. A Model for Estimating the Risk of Gastrointestinal Bleeding for Patients on Oral Anticoagulants and Interacting Medications. Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy. 2026;46(11). doi:10.1002/phar.70205
BibTeX
@article{GomezLumbreras2026,
author = {Gomez-Lumbreras, Ainhoa and Tawfik, Abdelrahman G and Reese, Thomas and Witt, Daniel M and Del Fiol, Guilherme and Malone, Daniel C},
title = {A Model for Estimating the Risk of Gastrointestinal Bleeding for Patients on Oral Anticoagulants and Interacting Medications},
journal = {Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy},
year = {2026},
volume = {46},
number = {11},
doi = {10.1002/phar.70205}
}
EUVIMED